The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: A systematic review and economic evaluation

Health Technology Assessment

Volumn 14, Issue 19, 2010, Pages 1-220

  Loveman, E ^a   Jones, J ^a   Hartwell, D ^a   Bird, A ^a   Harris, P ^a   Welch, K ^a   Clegg, A ^a  

^a Southampton Health Technology Assessments Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE;

ABSCESS; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG USE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FUNCTIONAL STATUS; HUMAN; INFECTION; INFECTION COMPLICATION; LEUKOPENIA; LIFE EXPECTANCY; LOW DRUG DOSE; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PNEUMONIA; PROGNOSIS; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RETREATMENT; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 77951461144     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14190     Document Type: Article

References (82)

1. Kabir Z, Connolly GN, Clancy L. Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. Ulster Med J 2008;77:31-5.
2. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007;75:56-63.
3. NICE. The diagnosis and treatment of lung cancer. London: NICE; 2005. URL: www.nice.org.uk/CG024NICEguideline. Accessed 3 November 2008.
4. Morris DE, Socinski MA, Detterbeck FC. Limited stage small cell lung cancer. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, editors. Diagnosis and treatment of lung cancer: an evidencebased guide for the practicing clinician. Philadelphia: WB Saunders; 2001. pp. 341-59.
5. Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 1999;74:809-16.
6. Cheng S, Evans WK, Stys-Norman D, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348-54.
7. Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003;4:CD001990.
8. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:S21-49.
9. Twigg L, Moon G, Walker S. The smoking epidemic in England. London: Health Development Agency; 2004.
10. Rivera MP, Detterbeck FC, Loomis DP. Epidemiology and classification of lung cancer. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, editors. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia: WB Saunders; 2001. pp.25-44.
11. Alberg AM, Ford JG, Samet JM. Epidemiology of lung cancer. ACCP evidence-based clinical practice guidelines. Chest 2007;132:S29-55.
12. Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 2006;10(3).
13. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008;9:649-56.
14. Bain C, Feskanich D, Speizer FE, Thun M, Hertzmark E, Rosner BA et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004;96:826-34.
15. Boffetta P, Trichopoulos D. Cancer of the lung, larynx and pleura. In Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. Oxford: Oxford University Press; 2002. pp. 248-80.
16. Fabricius P, Lange P. Diet and lung cancer. Monaldi Arch Chest Dis 2003;59:207-11.
17. Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with lung cancer. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2005. p. 80.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
19. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
20. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2005, England. Newport: HMSO; 2008. Series MB1 no. 36.
21. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
22. Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the lung in England and Wales up to 2001. Br J Cancer 2008;99:S40-2.
23. Cancer Research UK. UK lung cancer mortality statistics. London: Cancer Research UK; 2008. 11 August 2008.
24. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:S259-71S.
25. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol 2006;17(Suppl. 2):ii5-10.
26. The Information Centre for Health and Social Care. National Lung Cancer Audit. Key findings about the quality of care for people with Lung Cancer in England and Wales: Report for the audit period 2006. Leeds: Information Centre for Health and Social Care; 2007. URL: www.ic.nhs.uk/our-services/improvingpatientcare/more-about-the-audits/audit-reports/lung. Accessed 3 November 2008.
27. Welsh Cancer Intelligence & Surveillance Unit. Cancer incidence in Wales 2002-2006. Cardiff: WCISU; 2008. SA8/01. URL: www.wales.nhs.uk/sites3/Documents/242/incpub2006%5F31Jan08.pdf. Accessed 6 October 2008.
28. Cancer Research UK. UK lung cancer incidence statistics. London: Cancer Research UK; 11 August 2008.
29. Office for National Statistics. Cancer Survival: England and Wales, 1991-2001. Press release. 31 October 2003.
30. Cancer Research UK. UK lung cancer survival statistics. London: Cancer Research UK; 11 August 2008.
31. Hyde L, Yee J, Wilson R, Patno ME. Cell type and the natural history of lung cancer. JAMA 1965;193:52-4.
32. Simon GR, Turrisi A. Management of small cell lung cancer. ACCP evidence-based clinical practice guidelines. 2nd edn. Chest 2007;132:S32-9.
33. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-104.
34. Johnson BE, Grayson J, Makuch RW, Linnoila RI, Anderson MJ, Cohen MH, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 1990;8:396-401.
35. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597-604.
36. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to 18+ years: an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-20.
37. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991;99:1425-32.
38. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33.
39. Bremnes RM, Sundstrom S, Aasebo U, Kassa S, Hatlevolh R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5-year follow-up. Lung Cancer 2003;39:303-13.
40. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2008;4:631-8.
41. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5.
42. Gomersall LN. Imaging in lung cancer. Imaging 16:2004;1-9.
43. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hattoon M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-72.
44. Thatcher N, Eckardt J, Green M. Options for firstand second-line therapy in small cell lung cancer: a workshop discussion. Lung Cancer 2003;41:S37-41.
45. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001;12:23-7.
46. von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer 2003;41:S3-8.
47. Scottish Medicines Consortium (SMC). Topotecan (Hycamtin) for the treatment of patients with relapsed small cell lung cancer. URL: www.scottishmedicines.org.uk/smc/files/topotecan%20(Hycamtin)%20FINAL%20November%202007%20 for%20website.pdf366/07. Accessed 7 May 2007.
48. All Wales Medicines Strategy Group (AWMSG). Topotecan (HycamtinR) for small cell lung carcinoma. AWMSG Final Appraisal Report. URL: www.pcpoh.bham.ac.uk 2008. Accessed 7 October 2008.
49. Oliver E, Killen J, Kiebert G, Hutton J, Hall R, Higgins B, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001;56:785-90.
50. Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007. No. 54.
51. GlaxoSmithKline UK. Multiple technology appraisal of topotecan for the treatment of small cell lung cancer. GSK UK; 2008.
52. National Horizon Scanning Centre. Oral topotecan (Hycamtin) for small cell lung cancer. URL: www.pcpoh.bham.ac.uk2007. Accessed 7 October 2008.
53. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. York: York Publishing Services; 2001. CRD Report Number 4. 2nd edn.
54. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1980;47:207-14.
55. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
56. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92.
57. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
58. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-9.
59. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
60. Eckardt T, von Pawel J, Hainsworth JD, Corso S, Rinaldi D, Preston A, et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study [abstract]. Proc Am Soc Clin Oncol 2003;22:abstr. no. 2488.
61. Schiller J, von Pawel J, Shepherd F, Gralla R, Kleisbauer JP, Clark P, et al. Topotecan (t) versus (vs) cyclophosphamide (c), doxorubicin (a) and vincristine (v) for the treatment (tx) of patients (pts) with recurrent small cell lung cancer (sclc): a phase III study [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998;17:1755.
62. Sugawara S, Inoue A, Yamazaki K, Saijo Y, Gomi K, Ishimoto, et al. and North Japan Lung Cancer Study Group. Randomized, phase II trial comparing amrubicin with topotecan in patients (pts) with previously treated small cell lung cancer (SCLC). J Clin Oncol 2008;26(Suppl.)
63. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26(33):5401-6.
64. Chen L, Antras L, Duh M, Pickard S, Cella D, Neary M, et al. Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer? [abstract]. J Thoracic Oncol 2007;2(Suppl.4):S391-2.
65. O'Brien ME, Duh MS, Chen L, Antras L, Neary M, Gralla RJ. An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomized Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial (abstract). J Thoracic Oncol 2007;2(Suppl.4):S827.
66. Drummond MF, Sculpher MJ, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
67. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 26 January 2009.
68. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
69. Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2006;10(9).
70. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2007.
71. Glick HA, Doshi JD, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2007.
72. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (The "DEALE") II. Use in medical decision making. Am J Med 1982;73:889-97.
73. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26).
74. Hycamtin: summary of product characteristics. URL: www.emea.europa.eu/humandocs/PDFs/EPAR/Hycamtin/H-123-PI-en.pdf. Accessed 2 February 2009.
75. Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009. No. 57.
76. Department of Health. NHS Reference Costs 2006/07. URL:www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571. Accessed 2 February 2009.
77. Casemix Service. Guide to Unbundling. Version No 1.0. URL: www.ic.nhs.uk/webfiles/Services/casemix/Prep%20HRG4/Guide%20to%20Unbundling2.pdf.13-4-2007. Accessed 2 February 2009.
78. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.
79. Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2008. No. 56.
80. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics Discussion Paper no. 138. York: Centre for Health Economics, University of York; 1995.
81. NHS Centre for Reviews and Dissemination. NHS economic evaluation database handbook. URL: www.york.ac.uk/inst/crd/pdf/nhseed-handb07.pdfApr./2007. Accessed 20 August 2008.
82. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.